Teva Pharmaceutical Industries investors endured a tough yea...

Teva Pharmaceutical Industries investors endured a tough year with total loss of 4.1% vs market gain of around 7.9%. The longer term shareholders face 10% loss in past 5 years. Given the lack of sustained improvements in key metrics, optimism for the company's future is hard to find.